<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31690">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01788618</url>
  </required_header>
  <id_info>
    <org_study_id>COG REDUC</org_study_id>
    <nct_id>NCT01788618</nct_id>
  </id_info>
  <brief_title>Cancer and Disorders of Cognitive Functions and Quality of Life: &quot;Cognitive Rehabilitation in Patients Suffering From Cancer and Treated With Chemotherapy&quot;</brief_title>
  <official_title>Cancer and Disorders of Cognitive Functions and Quality of Life: &quot;Cognitive Rehabilitation in Patients Suffering From Cancer and Treated With Chemotherapy&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study aims to measure the impact of cognitive rehabilitation workshops on the
      development of cognitive functions and quality of life of patients expressing a cognitive
      complaint
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of our study was to evaluate, in patients treated for cancer expressing
      the cognitive complaint during or after treatment, interest workshops on improving cognitive
      rehabilitation felt their cognitive functions and their quality of life.

      The primary endpoint was the proportion of patients showing an improvement in the score of
      perceived deficiencies (score ranging from 0 to 72) of the FACT-Cog after treatment. The
      FACT-Cog is a self-administered questionnaire assessing the patients felt their cognitive
      difficulties (memory, attention, concentration) and the impact of these difficulties on
      their quality of life. The improvement is defined as an increase of 7 points &gt;= cognitive
      score won by the (a) patient (e) after the treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Proportion of patients showing an improvement in the score of perceived deficiencies (score ranging from 0 to 72) of the FACT-Cog after care</measure>
    <time_frame>up to 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate, in patients treated for cancer expressing a cognitive complaint during or after the treatment, the interest workshops on improving cognitive rehabilitation felt their cognitive function and quality of life.
Autoquestionnary FACT COG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the relationship between cognitive impairment and the parameters of the quality of life</measure>
    <time_frame>Baseline and month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cognitive assessment:
MMS, Test de Grober et Buschke, mémoire des chiffres (WAIS IV), séquence lettres-chiffres (WAIS IV), arithmétique (WAIS IV), Trail Making Test, Fluence verbale, D2, Code (WAIS IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the relationships between goals disorders (measured by neuropsychological tests) and the patients felt</measure>
    <time_frame>Baseline and month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cognitive assessment:
MMS, Test de Grober et Buschke, mémoire des chiffres (WAIS IV), séquence lettres-chiffres (WAIS IV), arithmétique (WAIS IV), Trail Making Test, Fluence verbale, D2, Code (WAIS IV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of different types of interest support the evolution of objective and subjective cognitive performance of patients</measure>
    <time_frame>Baseline and month 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cognitive assesment:
MMS, Test de Grober et Buschke, mémoire des chiffres (WAIS IV), séquence lettres-chiffres (WAIS IV), arithmétique (WAIS IV), Trail Making Test, Fluence verbale, D2, Code (WAIS IV)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cognitive exams at T0 and T3. Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group 1 (Homework)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cognitive exams at T0 and T3. These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group 2 ( telephone follow)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cognitive exams at T0 and T3. These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cognitive exams</intervention_name>
    <description>Psychopathological assessment (T0 and T3):
Scale of Spielberger
The self-administered questionnaire CES-D
Cognitive assessment(T0 and T3):
- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)
Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):
Self-assessment FACT-COG (T0,every months until T3)</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>The control group 1 (Homework)</arm_group_label>
    <arm_group_label>Control group 2 ( telephone follow)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standardized cognitive rehabilitation</intervention_name>
    <description>Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standardized home exercise</intervention_name>
    <description>These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog</description>
    <arm_group_label>The control group 1 (Homework)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow up by phone</intervention_name>
    <description>These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog</description>
    <arm_group_label>Control group 2 ( telephone follow)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years

          -  Solid tumor or haematological

          -  Chemotherapy and / or targeted therapy in the adjuvant or metastatic

          -  Sequential processing

          -  Complaints to subjective cognitive during or after (within one year after the end of
             chemotherapy and / or targeted therapy) treatment assessed by four items of FACT-COG
             (impact on quality of life). Score ≥ 4/16 questions Q35, Q37, Q38 and Q41 of FACT COG

          -  Patient in remission or pause therapeutic

          -  Lack of personality disorders and / or psychiatric disorder scalable

          -  No known brain metastases

          -  Lack of primary brain tumor

          -  Lack of analgesic treatment with opioids or Class 3

          -  Having signed informed consent to participate in the study

          -  Mastery of the French language

        Exclusion Criteria:

          -  Primary cancer of the central nervous system or brain metastases

          -  Pathology malignant hematologic

          -  Disorders of higher functions documented

          -  Pathology psychiatric scalable

          -  Use documented drug

          -  Patient or opioids analgesics in Class 3

          -  Consumption of alcohol

          -  Patient unable to respond to cognitive tests and cognitive rehabilitation

          -  Refusal to participate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence JOLY-LOBBEDEZ, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence JOLY-LOBBEDEZ, PHD</last_name>
    <phone>33 2 31 45 50 02</phone>
    <email>f.joly@baclesse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier RIGAL, MD</last_name>
    <phone>33 2 32 08 22 41</phone>
    <email>olivier.rigal@chb.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence JOLY-LOBBEDEZ, PHD</last_name>
      <phone>33 2 31 45 50 02</phone>
      <email>f.joly@baclesse.fr</email>
    </contact>
    <investigator>
      <last_name>Florence JOLY-LOBBEDEZ, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel SEVIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Djelila ALLOUACHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle LEVY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine NOAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe FRUCHART, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie LHEUREUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme BARRIERE, MD</last_name>
      <phone>33 4 92 03 11 32</phone>
      <email>Jerome.barriere@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jérôme BARRIERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc FERRERO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe FOLLANA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric François, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>46038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier RIGAL, MD</last_name>
      <phone>33 2 32 08 22 41</phone>
      <email>olivier.rigal@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier RIGAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah DAUCHY, MD</last_name>
      <phone>33 1 42 11 46 30</phone>
      <email>s.dauchy@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Sarah DAUCHY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 7, 2013</lastchanged_date>
  <firstreceived_date>February 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive functions</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
